Treatment Clinical Trials for Endometrial Cancer

Clinical trials are research studies that involve people. The clinical trials on this list are for endometrial cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-75 of 82

  • Pembrolizumab and Chemotherapy in Treating Patients with High-Grade Obesity-Driven Endometrial Cancer

    This early phase I trial studies how well pembrolizumab works before surgery and in combination with standard chemotherapy after surgery in treating patients with high-grade obesity-driven endometrial cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab before surgery and in combination with standard chemotherapy after surgery may work better in patients with endometrial cancer.
    Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

  • Megestrol Acetate with or without Pterostilbene in Treating Patients with Endometrial Cancer Undergoing Hysterectomy

    This phase II trial studies how well megestrol acetate with or without pterostilbene works in treating patients with endometrial cancer undergoing hysterectomy. Drugs used in chemotherapy, such as megestrol acetate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pterostilbene is an antioxidant found in blueberries or grapes, and it has been shown to be effective in killing tumor cells and reducing cancer burden. It is not yet known whether giving megestrol acetate with or without pterostilbene may work better in treating patients with endometrial cancer.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California

  • Rucaparib in Treating Patients with Stage III, IV or Endometrial Cancer That Has Either Spread or Has Come Back After Prior Treatment

    This phase II trial studies how well rucaparib works in treating patients with stage III or IV endometrial cancer that has either spread or has come back after prior treatment. Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: University of Colorado Hospital, Aurora, Colorado

  • Niraparib and Copanlisib in Treating Participants with Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    This phase Ib trial studies the best dose and side effects of niraparib and copanlisib in treating participants with endometrial, ovarian, primary peritoneal, or fallopian tube cancer that has come back. Niraparib and copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

    This phase I trial studies the side effects and best dose of mirvetuximab soravtansine and rucaparib camsylate in treating participants with endometrial, ovarian, fallopian tube or primary peritoneal cancer that has come back. Drugs such as mirvetuximab soravtansine are antibodies linked to a toxic substance and may help find certain tumor cells and kill them without harming normal cells. Rucaparib camsylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving mirvetuximab soravtansine and rucaparib camsylate may work better in treating participants with recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

    The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
    Location: Vanderbilt University / Ingram Cancer Center, Nashville, Tennessee

  • Atezolizumab and Bevacizumab in Treating Patients with Advanced, Recurrent, or Refractory Endometrial Cancer

    This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with endometrial cancer that has spread to other places in the body, has come back, or does not respond to treatment. Immunotherapy with atezolizumab and bevacizumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread.
    Location: Stephenson Cancer Center, Oklahoma City, Oklahoma

  • Nivolumab with or without Ipilimumab in Treating Participants with Recurrent or High Grade Gynecologic Cancer with Metastatic Peritoneal Carcinomatosis

    This phase Ib trial studies the side effects and best dose of nivolumab with or without ipilimumab in treating participants with female reproductive cancer that has come back or is high grade and has spread extensively throughout the peritoneal cavity. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Bevacizumab and Rucaparib in Treating Patients with Recurrent Cervical or Endometrial Carcinoma

    This phase II trial studies how well bevacizumab and rucaparib work in treating patients with cervical or endometrial cancer that has come back. Immunotherapy with monoclonal antibodies, such as bevacizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving bevacizumab and rucaparib may be helpful in shrinking the tumors, keeping them from growing or spreading, or helping patients live longer.
    Location: Stephenson Cancer Center, Oklahoma City, Oklahoma

  • Stereotactic Body Radiation Therapy in Treating Patients with Recurrent Primary Ovarian or Uterine Cancer

    This phase I trial studies the side effects and best dose of stereotactic body radiation therapy in treating patients with ovarian or uterine cancer that has come back. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.
    Location: University of Colorado Hospital, Aurora, Colorado

  • Vaginal Cuff Brachytherapy Followed by Carboplatin and Paclitaxel in Treating Patients with Stage II Endometrial Cancer after Surgery

    This phase II trial studies how well vaginal cuff brachytherapy (radiation to the upper part of the vagina) followed by carboplatin and paclitaxel works in treating patients with stage II endometrial cancer after surgery. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carboplatin and paclitaxel following vaginal cuff brachytherapy may work better than the standard treatment of radiation to the vagina or entire pelvis.
    Location: Stephenson Cancer Center, Oklahoma City, Oklahoma

  • Selumetinib and Olaparib in Treating Participants with Relapsed or Refractory and Advanced Endometrial, Ovarian, or Other Solid Tumors with RAS Pathway Alterations

    This phase I / Ib trial studies the side effects and best dose of selumetinib and olaparib in treating participants with endometrial, ovarian, or other solid tumors with RAS pathway alterations that have come back or do not respond to treatment and have spread to other places in the body. Selumetinib and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Ribociclib, Everolimus, and Letrozole in Treating Participants with Advanced or Recurrent Endometrial Cancer

    This phase II trial studies how well ribociclib, everolimus, and letrozole work in treating participants with endometrial cancer that has spread to other areas of the body or has come back. Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as everolimus, and letrozole, work in different ways to sop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or b stopping them from spreading. Giving ribociclib, everolimus, and letrozole may work better in treating participants with endometrial cancer.
    Location: 2 locations

  • Pembrolizumab in Treating Patients with Recurrent or Metastatic Hypermutated / Ultramutated Endometrial Cancer

    This phase II trial studies how well pembrolizumab works in treating patients with endometrial cancer that has a high number of genetic mutations (hypermutated / ultramutated) and has come back (recurrent) or that has spread to other parts of the body (metastatic). Immunotherapy with antibodies, such as pembrolizumab, may remove the brake on the body's immune system and may interfere with the ability of tumor cells to grow and spread.
    Location: Yale University, New Haven, Connecticut

  • Metformin Hydrochloride and Doxycycline in Treating Patients with Localized Breast, Uterine, or Cervical Cancer

    This phase II trial studies how well metformin hydrochloride works together with doxycycline in treating patients with localized breast, uterine, or cervical cancer. Metformin hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Doxycycline may stop the growth of bacteria by keeping them from making proteins and minimized the toxic side effects of anti-cancer therapy. It is not yet known whether giving metformin hydrochloride together with doxycycline may be a better way in treating patients with localized breast, uterine, or cervical cancer.
    Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

  • ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

    The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Pembrolizumab in Treating Patients with Ovarian, Endometrial, Fallopian Tube, or Primary Peritoneal Cancer

    This pilot early phase I trial studies side effects and how well pembrolizumab works in treating patients with ovarian, endometrial, fallopian tube, or primary peritoneal cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: Duke University Medical Center, Durham, North Carolina

  • Selective Surgical Staging in Predicting Lymph Node Removal in Patients with Endometrial Cancer Undergoing Surgery

    This clinical trial evaluates selective surgical staging in the treatment of women with early stage endometrial cancer (EC). The standard treatment for women with EC includes the surgical removal of the uterus (hysterectomy), both fallopian tubes and ovaries (bilateral salpingo-oophorectomy), and sometimes the lymph nodes (lymph node sampling). Even though this is a common malignancy, gynecologic oncologists still disagree on the best treatment for early EC. Some surgeons choose not to remove any lymph nodes, some perform lymph node sampling, and others remove all related lymph nodes (lymphadenectomy). Since lymph node removal is associated with adverse events, it should only be performed when necessary. By performing a systematic examination of the uterus after its removal (intraoperative consultation, IOC), doctors can better determine whether or not lymphadenectomy should be performed. Using this treatment strategy, the extent of the surgery is tailored to match the risk that the woman’s lymph nodes will be involved by cancer. After completion of the IOC, women with high-risk cancers are treated with lymphadenectomy while women with low-risk cancers are not.
    Location: University of Kentucky / Markey Cancer Center, Lexington, Kentucky

  • Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol

    To determine if treatment with cisplatin and radiation followed by carbo and taxol reduces the rate of recurrence when compared to sandwich therapy.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients with High-Risk Endometrial Cancer

    This phase II trial studies how well radiation therapy, paclitaxel, and carboplatin work in treating patients with high-risk endometrial cancer. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Giving radiation therapy with chemotherapy may kill more tumor cells.
    Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York

  • Pembrolizumab (MK-3475) Plus Lenvatinib (E7080 / MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)

    The purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma. It is hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for progression-free survival (PFS) per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR). It is also hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for overall survival (OS).
    Location: 2 locations

  • A Dose Escalation Study of PF‑06939999 in Participants With Advanced or Metastatic Solid Tumors.

    This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.
    Location: 2 locations

  • A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

    This is a Phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD and clinical activity of AB928 in combination with AB122 in participants with advanced malignancies.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

    The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Phase 1 / 2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)

    The purpose of Part 1 (Phase 1b) is to evaluate the general safety and tolerability of repeated 21-day cycles of AL3818 therapy, and to reevaluate the maximum tolerated dose (MTD). The purpose of Part 2 (Phase 2a) is to evaluate the efficacy of repeated 21-day cycles of AL3818 therapy preliminary efficacy of AL3818 in subjects with recurrent or metastatic endometrial, ovarian or cervical cancer.
    Location: See Clinical Trials.gov